Chinese biotechnology company DualityBio (HKEX:9606) announced on Monday that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting antibody-drug conjugate (ADC) DB-1310.
This designation is for the treatment of adult patients with advanced, unresectable or metastatic nonsquamous non-small cell lung cancer (nsqNSCLC) with an EGFR exon 19 deletion or L858R mutation with disease progression on or after treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy.
DB-1310 is a novel ADC targeting HER3 developed using DualityBio's proprietary DITAC platform. First-in-human Phase I/IIa clinical trial data of DB-1310 demonstrated encouraging efficacy and a manageable safety profile in patients with advanced solid tumours who had failed standard therapies.
AN2 Therapeutics and DNDi partner to advance oral therapy for chronic Chagas disease
Opus Genetics partners with Global RDH12 Alliance to advance gene therapy for childhood blindness
Lantern Pharma reports first complete response with LP-284 in heavily pretreated lymphoma patient
DualityBio's HER3 ADC DB-1310 granted US FDA Fast Track Designation
Ionis publishes positive Phase 3 data supporting donidalorsen as HAE prophylactic
Orion and Bayer receive EU approval for darolutamide in metastatic hormone-sensitive prostate cancer
Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy
CorestemChemon partners with ATG Lifetech to provide next-gen preclinical services
Philips launches ECG AI Marketplace to streamline cardiac diagnostics
Nicox signs licensing deal with Kowa for NCX 470 rights
Citius Oncology prices USD9.0m public offering
Genetic Leap's GL-IL2-138 receives FDA IND clearance
Amphix Bio's AMFX-200 receives US FDA Orphan Drug Designation to treat acute spinal cord injury